Explore the details of the Biogen Inc. V. Zydus Worldwide Dmcc case under case number 1:23-cv-00732 involving a cause of action for Patent Infringement. Review key information about the parties involved, the patents in question, and the docket entries.

Case Details

Case Number
1:23-cv-00732
Filing Date
Jul 6, 2023
Cause of Action
Patent Infringement
Status
-
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Alkermes Pharma Ireland Limited -
Zydus Worldwide DMCC -
Biogen Inc. -

Patents Involved in the Case

Patents not found - set an alert to get notified when patents are added.

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

May 13, 2025ORAL ORDER: Having considered the parties' Interim Status Report (D.I. 56), IT IS HEREBY ORDERED that, by no later than Friday, May 23, 2025, the parties shall meet and confer and submit a joint letter, not to exceed three (3) pages, informing the Court whether the discovery disputes identified in the Interim Status Report (D.I. 56 at 2) remain in dispute. To the extent that those discovery disputes remain in dispute, the joint letter shall (1) identify the specific issues that remain in dispute; (2) set forth each party's position on each dispute and the legal authority for each party's respective position; and (3) explain why the parties were unable to reach agreement on each issue. ORDERED by Judge Gregory B. Williams on 5/13/2025. (lnb) (Entered: 05/13/2025)PACER Document
May 21, 2025Pro Hac Vice Fee - Credit Card Payment received for Alyssa A. Dolan. ( re 75 MOTION for Pro Hac Vice Appearance of Attorney Alyssa A. Dolan )( Payment of $ 50, receipt number ADEDC-4692662).(Tigan, Jeremy) (Entered: 05/21/2025)PACER Document
May 23, 2025SO ORDERED, re 75 MOTION for Pro Hac Vice Appearance of Attorney Alyssa A. Dolan filed by Biogen Swiss Manufacturing GmbH, Alkermes Pharma Ireland Limited, Biogen Inc. Signed by Judge Gregory B. Williams on 5/23/2025. (lnb)PACER Document
Jun 27, 2025ORAL ORDER: The five (5) day bench trial in this action is double-booked on the Court's calendar with a jury trial beginning on July 28, 2025. Neither case has settled as of this date. The Court has availability to reschedule the bench trial in this action to begin on July 14, 2025, or some other date during that week so that the trial can be completed before July 25, 2025. Otherwise, the Court has availability to reschedule the bench trial in this action to begin on December 1, 2025. No other time in 2025 to complete the trial is available on the Court's calendar at this time. WHEREFORE, IT IS HEREBY ORDERED that counsel for the parties should meet and confer promptly and, by no later than 5:00 p.m. on July 8, 2025, file a joint status report of no longer than three (3) pages advising the Court of whether trial in this action remains necessary and, if so, whether the parties prefer the Court to reschedule the bench trial in this action to begin on July 14, 2025 or some other date during that week so the trial can be completed before July 25, 2025, or to reschedule the trial to begin on December 1, 2025. The parties also should advise in their joint status report whether they believe the case could be tried in less than five (5) days. Of course, the bench trial in this action will not need to be rescheduled if the jury trial (also scheduled to begin on July 28, 2025) settles before between today and July 28, 2025. ORDERED by Judge Gregory B. Williams on 6/27/2025. (lnb) (Entered: 06/27/2025)PACER Document
Jul 9, 2025ORAL ORDER: Having considered Defendants' letter of July 8, 2025 (D.I. 79) and Plaintiff's letter of July 9, 2025 in response (D.I. 83), IT IS HEREBY ORDERED that, on or before August 9, 2025, the parties shall either file a stipulation and proposed order of dismissal or an updated joint status report advising the Court of the status of the action and whether trial is still necessary. If no settlement has been reached as of August 8, 2025, in the joint status report, the parties also shall inform the Court whether both parties want the Court to refer this action to a Magistrate Judge for mediation. ORDERED by Judge Gregory B. Williams on 7/9/2025. (lnb) (Entered: 07/09/2025)PACER Document
Jul 9, 2025ORAL ORDER: In the event that the jury trial action that is double-booked with this action for trial beginning on July 28, 2025 does not settle and this action needs to be rescheduled, this action will be rescheduled for a four (4) day bench trial to begin on January 12, 2026 at 9:30 a.m. On the other hand, in the event the jury trial that is double-booked with this action for trial beginning on July 28, 2025 does settle, this parties in this action should be prepared to proceed with trial beginning on July 28, 2025. The Court will advise the parties in this action, by no later than July 23, 2025, whether this action is being rescheduled for trial to begin on January 12, 2026, at 9:30 a.m. ORDERED by Judge Gregory B. Williams on 7/9/2025. (lnb) (Entered: 07/09/2025)PACER Document
Jul 17, 2025SO ORDERED, re 88 Stipulation filed by Biogen International GmbH, Alkermes Pharma Ireland Limited, Biogen Inc., Biogen Swiss Manufacturing GmbH terminated. Signed by Judge Gregory B. Williams on 7/17/2025. (lnb)PACER Document
Jul 15, 2025REDACTED VERSION of 80 Status Report by Alkermes Pharma Ireland Limited, Biogen Inc., Biogen Swiss Manufacturing GmbH. (Attachments: # 1 Stipulation)(Yenerall, Ben) (Entered: 07/15/2025)Attachment
Jul 21, 2025MEMORANDUM ORDER DEFERRING Plaintiffs' Motion in Limine to Preclude Defendants from Offering Undisclosed Opinions of Dr. Benjamin Greenberg. Signed by Judge Gregory B. Williams on 7/21/2025. (lnb)PACER Document
Jul 21, 2025MEMORANDUM ORDER DEFERRING Plaintiffs' Motion in Limine to Preclude Defendants from Offering Undisclosed Expert Opinions of Dr. Criag Lindsley. Signed by Judge Gregory B. Williams on 7/21/2025. (lnb)PACER Document